| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10039946 | HBV | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
| TVIS10040735 | HBV | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
| TVIS20001818 | HPV | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
| TVIS20010059 | HPV | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
| TVIS44025444 | HTLV-1 | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
| TVIS44016388 | HTLV-1 | ENSG00000142319.19 | protein_coding | SLC6A3 | No | No | 6531 | Q01959 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SLC6A3 |
|---|---|
| DrugBank ID | DB01156 |
| Drug Name | Bupropion |
| Target ID | BE0000647 |
| UniProt ID | Q01959 |
| Regulation Type | inhibitor |
| PubMed IDs | 12183670; 12185406; 12589396; 14550679; 15787205; 11752352; 9537821; 15361919; 28220701; 27541930; 16923164 |
| Citations | Miller DK, Sumithran SP, Dwoskin LP: Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther. 2002 Sep;302(3):1113-22.@@Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl). 2002 Aug;163(1):102-5. Epub 2002 Jul 13.@@Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Seibyl JP, Innis RB: Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003 Feb;28(2):413-20. Epub 2002 Jul 19.@@Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B: In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003 Oct 15;54(8):800-5.@@Szabo Z, Argyelan M, Kanyo B, Pavics L, Janka Z: [Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]. Neuropsychopharmacol Hung. 2004 Jun;6(2):79-81.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.@@Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S: A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166.@@Shalabi AR, Walther D, Baumann MH, Glennon RA: Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. ACS Chem Neurosci. 2017 Jun 21;8(6):1397-1403. doi: 10.1021/acschemneuro.7b00055. Epub 2017 Feb 27.@@Simonsen U, Comerma-Steffensen S, Andersson KE: Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction. Basic Clin Pharmacol Toxicol. 2016 Oct;119 Suppl 3:63-74. doi: 10.1111/bcpt.12653.@@Mortensen OV, Amara SG: Gain of function mutants reveal sites important for the interaction of the atypical inhibitors benztropine and bupropion with monoamine transporters. J Neurochem. 2006 Sep;98(5):1531-40. doi: 10.1111/j.1471-4159.2006.04060.x. |
| Groups | Approved |
| Direct Classification | Alkyl-phenylketones |
| SMILES | CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1 |
| Pathways | |
| PharmGKB | PA448687 |
| ChEMBL | CHEMBL894 |
